Investigational drug · Phase 2
ABBV-932
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bipolar I or II Disorder, Generalized Anxiety Disorder (GAD), Bipolar I Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
10
Any phase or sponsor naming "ABBV-932"
First trial start
2024
Oct 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-932", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bipolar I or II Disorder
- Generalized Anxiety Disorder (GAD)
- Bipolar I Disorder
- Bipolar II Disorder
Approved drugs for the same conditions: Bipolar disorder · Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-932" as an intervention, largest first.
- Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06846320 · 315 participants (planned) · Start Apr 29, 2025 · Primary completion Nov 2026
Drug: ABBV-932; Placebo for ABBV-932 and 1 more · For: Generalized Anxiety Disorder (GAD)
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 52 sites in all
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06605599 · 161 participants · Start Oct 15, 2024 · Primary completion Nov 12, 2025
Drug: ABBV-932; Placebo for ABBV-932 · For: Bipolar I Disorder; Bipolar II Disorder
Sites: Dothan, Alabama; Anaheim, California; Colton, California · 40 sites in all
- Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult ParticipantsPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05738850 · 104 participants · Start Feb 15, 2023 · Primary completion May 31, 2024
Drug: ABBV-932; Placebo · For: Generalized Anxiety Disorder (GAD); Healthy Participants
Sites: Anaheim, California; Grayslake, Illinois
- Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07220460 · 84 participants · Start Sep 30, 2025 · Primary completion Mar 2027
Drug: ABBV-932 · For: Bipolar I or II Disorder
Sites: Phoenix, Arizona; Anaheim, California; Colton, California · 49 sites in all
AbbVieAbbVie (ABBV)
NCT06024239 · 72 participants · Start Aug 31, 2023 · Primary completion Mar 4, 2025
Drug: ABBV-932; Placebo for ABBV-932 · For: Healthy Volunteers; Generalized Anxiety Disorder (GAD); Bipolar Disorder (BPD)
Sites: Los Alamitos, California; Grayslake, Illinois; Marlton, New Jersey
AbbVieAbbVie (ABBV)
NCT07024797 · 20 participants · Start Aug 21, 2025 · Primary completion Dec 8, 2025
Drug: ABBV-932; Placebo for ABBV-932 · For: Healthy Volunteer
Sites: Shanghai, China
AbbVieAbbVie (ABBV)
NCT07071532 · 20 participants (planned) · Start Aug 20, 2026 · Primary completion Feb 2027
Drug: ABBV-932; Itraconazole · For: Bipolar Disorder
Sites: Los Alamitos, California; Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT06300580 · 11 participants · Start Aug 21, 2024 · Primary completion May 26, 2025
Drug: ABBV-932 · For: Healthy Volunteers
Sites: Harrow, United Kingdom
- A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult ParticipantsCompleted
AbbVieAbbVie (ABBV)
NCT06849791 · 9 participants · Start Feb 26, 2025 · Primary completion May 8, 2026
Drug: ABBV-932; ABBV-932 · For: Healthy Volunteer
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT06953934 · 8 participants · Start May 4, 2026 · Primary completion Sep 14, 2026
Drug: ABBV-932 · For: Healthy Volunteer
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.